Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300

1 PRESS RELEASE Adocia Announces Positive Preclinical Results for a Concentrated Ultra- Fast insulin, BioChaperone® Lispro U300  BioChaperone Lispro U300 could be the first concentrated formulation of an insulin analog to be ultra-fast acting  New, proprietary insulin formulation could meet the requirements of diabetic patients prescribed large insulin doses  BioChaperone Lispro U300 is the fourth insulin-based product developed by Adocia Lyon, France, June 10 th, 2014 - Adocia (Euronext Paris: FR0011184241 – ADOC) announced today positive preclinical results for its concentrated formulation of insulin lispro, BioChaperone Lispro U300 . The study showed that BioChaperone Lispro U300 had a faster onset of action than Humalog® (Eli Lilly) at 100 IU/mL. Adocia’s concentrated formulation uses the proprietary technology BioChaperone® which succeeds in accelerating the absorption of prandial insulins and which has already been used in two products currently in clinical development (BioChaperone Lispro and HinsBet®). Prandial insulin is administered to ensure a better glycemic control in patients following meals. This control is critical in ord er to avoid hyperglycemic events which are the main cause of diabetes-related complications. A growing number of overweight patients and patients with severe insulin resistance require higher insulin dosage. For these patients, there is a need to develop c oncentrated insulin solutions, in order to inject higher doses at constant volume. However, preserving efficacy of concentrated prandial insulins is a challenge, since increasing insulin concentration is known to slow its absorption kinetics and hamper its fast action. The preclinical data show BioChaperone Lispro U300 has an ultra -fast action compared to Humalog U100, equivalent to the one obtained with BioChaperone Lispro U100. “We are very excited to have demonstrated that our technology improves prandial insulin analogs medical performance at high concentration” commented Olivier Soula, General Deputy Manage r and Director of R&D at Adocia . “To our knowledge , BioChaperone Lispro U300 is the first concentrated formulation of an insulin analog to be ultra -fast acting . The goal with BioChaperone Lispro U300, just like BioChaperone Lispro U100, is to get closer to the endogenous insulin secretion observed in h ealthy subjects following meals.” In this preclinical cross-over study, BioChaperone Lispro U300 was compared to Humalog in a model established and correlated to human . This correlation was based on the phase 2 BioChaperone Lispro clinical results. The comparison of the pharmacodynamics and pharmacokinetics of BioChaperone Lispro 2 U300 and Humalog demonstrated a faster action for BioChaperone Lispro U300, despite the increased concentration. “BioChaperone Lispro U300 , our fourth insulin based product, reinforces our portfolio of insulin formulations, which is one of the most complete in the field. This concentrated formulation of insulin lispro has the potenti al to differentiate Adocia from other insulin players . Furthermore, this extension of our product portfolio underscores our motivation to innovate in the insulin therapy field in order to significantly improve the lives of patients”, said Gérard Soula, CEO of Adocia. A phase 1/2 clinical s tudy with BioChaperone Lispro U3 00 is scheduled for the first half of 2015. The BioChaperone technology for prandial insulin is protected by six families of patents valid for some of them until 2033. About ultra-concentrated prandial insulin More and more patients are requiring larger quantities of prandial insulin to correct glucose levels f ollowing meals. This is due on the one hand to the evolution of the illness which leads to insulin resistance, and on the other hand to the weight gain of a significant group of type 2 diabetic patients, which creates a limit to the absorption of insulin subcutaneously. These two factors contribute to the increase in the insulin dose injections for the same patient over the years. Currently, the only concentrated prandial insulin on the market is the human insulin at 500 IU/mL (Humulin® R500, Eli Lilly) whose acting time is significantly slower than those of modern prandial insulins at 100 IU/mL such as Humalog, NovoLog® (Novo Nordisk) and Apidra® (Sanofi). The formulation of the insulin Lispro at 300 IU/mL with BioChaperone could have an action time comparable to the ultra-fast BoiChaperone Lispro U100 currently in clinical development with very promising phase 2 results. About diabetes Diabetes is a chronic condition in which the person has high blood glucose (hyperglycemia), either because insulin production is inadequate, or because the body's cells do not respond properly to insulin, or both. Over time, chronic hyperglycemia contribut es to disease progression and results in macrovascular and microvascular complications. Worldwide, more than 382 million individuals are currently suffering from diabetes, with a forecast of 592 million individuals by 2035, i.e. an average increase of 55%, and an increase of as much as 70% in emerging countries. (Source: International Diabetes Federation, 2013). About Adocia To be a global leader in the delivery of insulins and therapeutic proteins Adocia is clinical -stage biotechnology company that specia lizes in the development of innovative formulations of already-approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. Adocia’s proprietary BioChaperone® technological platform is designed to enhance the effectivenes s and safety of therapeutic proteins and their ease of use for patients. Adocia has successfully completed two Phase I and II studies of a fast -acting human insulin formulation, two Phase I and II studies of an ultra -fast-acting insulin lispro and a Phase I/II of a unique combination of insulin glargine, the gold-standard of basal insulin and insulin lispro, a fast -acting insulin analog. Dose -escalation Phase IIa studies of all three products are scheduled for the third and the fourth quarter 2014. The company has also obtained positive results in a Phase I/II study of a diabetic -foot-ulcer-healing product based on PDGF-BB (Platelet-Derived Growth-Factor BB). A phase III clinical trial dossier has been filed with Indian regulatory authorities, and the trial is expected to start at the beginning of the third quarter 2014. Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold-standard biologics for the treatment of various chronic pathologies (cancer, inflammation, etc.). Adocia is engaged in collaborative programs with two major pharmaceutical companies in this field. Fighting cancer with targeted treatments DriveIn® is a nanotechnology which is remarkably efficient in delivering active compounds into canc er cells. This new platform constitutes an exceptional opportunity to enter the oncology market by improving the efficacy of both already approved treatments and novel proprietary molecules. “Innovative medicine for everyone, everywhere” 3 Adocia’s therapeu tic innovations aim at providing solutions in a profoundly changing global pharmaceutical and economic context, characterized by (i) an increased prevalence and impact of the targeted pathologies, (ii) a growing and ageing population, (iii) a need to contr ol public health expenditures and (iv) an increasing demand from emerging countries. Adocia is listed on the regulated market of Euronext Paris (ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA, ADOC.FP) and its share price is included in the Next Biotech index. American Depositary Receipts representing Adocia common stock are traded on the US OTC market under the ticker symbol ADOCY. For more information, visit www.adocia.com Contact Gerard Soula - [email protected] Chairman and CEO of Adocia Tel.: +33 4 72 610 610 Press Relations ALIZE RP Caroline Carmagnol [email protected] Tel.: +33 170 225 390 Disclaimer This press release contains certain forward -looking statements concerning Adocia and its business. Such forward - looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contai ned in such forward -looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the ‘Risk Factors ’ section of the Reference Document registered by the Autorite des marches f inanciers on April 2 4, 201 4 under number R .14-020 (a copy of which is available on hhtp://www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward -looking statements contained in this press release are als o subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.

The release as fetched from its publisher. adocia.com ↗